Highlighted Services
Fully Human Monoclonal Antibodies
Precision Antibody offers fully human antibody development using transgenic mice. We are capable of developing a large number of antigen-specific clones producing fully human IgG in about 60 days. Precision Antibody uses their proprietary procedures and platform to rapidly generate application specific monoclonal antibodies (mAbs). Please inquire.
Anti-Idiotypic Monoclonal Antibodies
Precision Antibody has extensive experience developing anti-idiotypic antibodies (anti-idiotype) for pharmacokinetic (PK) and pharmacodynamic studies. Our team of immunologists has developed a successful immunization protocol that has vastly improved the generation of anti-idiotypic antibodies. We have developed anti-idiotypes for large and small biotechnology and pharmaceutical customers.
Diagnostic and Therapeutic Monoclonal Antibodies
Precision Antibody has become a household name for customized mAb development. Our team of scientists will develop a strategy to match the needs of your diagnostic or therapeutic program, including modifying the scale and scope of the program to identify mAbs for drug development.
Standard Reagent/Antibody Tool
Rapid monoclonal antibody development to generate Monoclonal Antibodies for basic research in immunoassays. Precision Antibody can target proteins, peptides, small molecules and other antigens to make mAbs as antibody tools. mAbs are identified for binding utility and can be characterized for Ab production and binding affinity.
Recent News
Precision Antibody’s proprietary technology develops fully human antibodies in ~60 days
Precision Antibody’s proprietary technology develops fully human antibodies in ~60 days Precision Antibody has an exclusive license agreement with trans-chromosomic (Tc) mice carrying mini-chromosomes with megabase-sized human immunoglobulin (Ig) loci. Precision Antibody has developed a proprietary method to develop a strong immune response against therapeutic targets in three weeks, enabling …CPTAC Ras Initiative Paper
Precision Antibody contributes to the development of novel antibody reagents for the RAS signaling network The National Cancer Institute (NCI)’s RAS initiative has been working with the Office of Cancer Clinical Proteomics Research (OCCPR) to launch a proteomic assay development and characterization project targeting RAS-associated pathways. The goal of this …Identification of an Internalizing Cancer Target for Novel Antibody Drug Conjugate Development by A&G Pharmaceutical and Precision Antibody Researchers
Precision Antibody and A&G Pharmaceutical are pleased to announce the publication, in PLOS One, of the results of their collaborative study about the identification of Prostaglandin F2 receptor negative regulator as a cancer cell surface target and the isolation of internalizing antibody for antibody drug conjugate development.ARV-7 Press Release
Precision Antibody is pleased to announce the recent article published in Cancers 2020, by Konig et al entitled “Expression of AR-V7 (androgen receptor variant 7) protein in granular cytoplasmic structures is an independent prognostic factor in prostate cancer patients”.